SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

The Metals Company (TMC) is trending due to significant U.S. regulatory advancements, including NOAA's expedited deep-sea mining permit processes and an upcoming Congressional hearing featuring its CEO. The community is actively discussing the national security implications of critical deep-sea minerals and the potential for a short squeeze, fueling strong bullish sentiment for the company's future.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is experiencing a significant surge, driven by widespread anticipation surrounding its upcoming earnings report and growing speculation about substantial government contracts tied to US-based chip manufacturing. The community is actively debating whether the rally reflects genuine strategic re-positioning in AI and foundry services, or if it's a pre-earnings pump susceptible to "sell the news" profit-taking, fueling both FOMO and short squeeze narratives.

The Kraft Heinz Co. engages in the manufacture and market of food and beverage products. It operates through the North America and International geographical segments. The company was founded on July 2, 2015, and is headquartered in Pittsburgh, PA.

Kraft Heinz Co

Kraft Heinz is a hot topic following Berkshire Hathaway's registration to potentially divest its substantial stake, sparking intense debate among investors. The community is sharply divided between those who see the recent price decline and strong dividend yield as a compelling buying opportunity for an undervalued consumer staple and those concerned about the company's historical underperformance and mounting competition from private label brands. The upcoming 2026 corporate split adds further speculation on whether it will truly unlock long-term value for the iconic food giant.

$SWEAT is the beating heart of the Movement Economy—a groundbreaking token that transforms physical activity into real-world value. Minted through movement, $SWEAT rewards your steps with a crypto asset that you can earn, trade, or grow. The team states that their app has increased their users’ physical activity by an average of 20%, creating a healthier society and reducing burdens on global healthcare systems. With over 20 million holders, SWEAT is eliminating barriers and making Web3 accessible to everyone, one step at a time.

Sweat Economy

Sweat Economy (SWEAT) is trending as its innovative move-to-earn model continues to generate buzz, rewarding users for physical activity. The community is actively discussing recent token burns, its evolving utility as a multi-chain gas token, and new Web3 integrations, fueling optimism for its long-term potential within the crypto ecosystem.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is experiencing significant bullish momentum driven by promising five-year follow-up data for its personalized cancer vaccine in combination with Keytruda, with many in the community viewing this as a transformative breakthrough for mRNA technology in oncology. This news, coupled with a strong financial outlook and discussions around a potential short squeeze, is fueling investor optimism and a reevaluation of the company's future beyond its initial vaccine success.

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

BOIL is experiencing a dramatic surge as a severe polar vortex brings extreme cold to much of the US, driving high natural gas heating demand and setting up expectations for significant storage withdrawals. The community is buzzing with talk of a potential short squeeze, recognizing the "widow maker" volatility inherent in these leveraged natural gas movements, as traders weigh the powerful weather catalysts against the rapid price run.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is experiencing a significant surge, fueled by reports of unprecedented memory chip shortages and substantial price hikes across the industry for HBM and DRAM, critical components for the AI buildout. The community is intensely debating the stock's parabolic ascent, with many bulls highlighting strong fundamentals and expanding margins, while skeptics warn of an overextended "blow-off top." This momentum reflects a perceived shift in memory demand from cyclical to sustained growth driven by AI infrastructure, driving analyst upgrades and enthusiastic long-term conviction.

PAVmed, Inc. is a multi-product life sciences company, which engages in the innovation, development, acquisition, and commercialization of products that target unmet medical needs with large addressable market opportunities. Its products include Lucid Diagnostics and Veris Health. The company was founded by Lishan Aklog and Brian J. deGuzman on June 26, 2014 and is headquartered in New York, NY.

PAVmed Inc

PAVmed is currently trending following its subsidiary, Lucid Diagnostics, securing a contract with the U.S. Department of Veterans Affairs for its EsoGuard Esophageal DNA Test, significantly expanding access to esophageal precancer screening. This news has sparked considerable community excitement, with traders noting the stock's low float and discussing the potential for a substantial short squeeze, drawing comparisons to other recent explosive movers in the market.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is actively discussed following a Neutron rocket Stage 1 tank rupture during qualification testing, generating community debate between those who view it as a routine developmental stress-test and others who anticipate potential launch delays. Bulls highlight this as a necessary de-risking step, pointing to the company's robust defense contracts, consistent Electron launch success, and strong financial position as key growth drivers. Meanwhile, the broader market watches closely for updates on Neutron's schedule and the company's valuation amidst its ambitious space systems expansion.

Telcoin is a multi-national fintech company  integrating blockchain technology, telecommunications, and digital banking to revolutionize global finance. It aims to provide borderless, instant, and affordable financial services to mobile phone users worldwide. Telcoin offers the Telcoin Wallet, a multi-signature DeFi wallet supporting more than 100 digital assets and remittances to eWallets and bank accounts globally. Telcoin is regulated as a Virtual Asset Service Provider in the EU (Lithuania) and Argentina, a Major Payment Institution in Singapore, and a Money Services Business in the US, Canada, and Australia.   Telcoin is designed to complement telecom, mobile money, and e-wallet partners globally with both traditional fiat and blockchain transaction rails that underpin our fast and affordable digital financial service offerings. Telcoin combines the best parts of the burgeoning DeFi ecosystem with our compliance-focused approach to each market, ensuring that the company takes on a fraction of traditional financial counterparty, execution, and custody risks.  The Telcoin Association is a Swiss non-profit organization domiciled in Lugano, Switzerland and is governed by a decentralized group of Miner Councils that run the various aspects of the Telcoin Platform, including the management of the Telcoin (TEL) token. Read more about the Telcoin Association [here](https://www.telcoin.org).

Telcoin

Telcoin ($TEL) is experiencing significant community discussion following its final charter approval to launch a Digital Asset Bank in Nebraska, a pivotal regulatory milestone positioning it to issue the first bank-issued, on-chain US Dollar stablecoin, eUSD. This development, coupled with recent listings on major exchanges like Kraken and Uphold, is fueling bullish sentiment and talks about TEL's potential to bridge traditional finance and decentralized finance. Enthusiasts highlight the TEL token's utility for network transactions and its fixed supply, anticipating substantial long-term growth as a compliant, real-world utility project.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Analysts see greater upside in Novavax, while Moderna carries a ‘Hold’ rating despite stronger gains over the past year.</li><li>Moderna was in focus after updated cancer vaccine data, while Novavax drew attention following its Pfizer licensing deal.</li><li>Retail sentiment on Stocktwits was 'extremely bullish' for both stocks, with message activity sharply higher over the past year.</li></ul><p>Wall Street is&nbsp;a bit&nbsp;split on Moderna and Novavax, with analysts favoring upside in one name even as the other has outperformed over the past year.</p><h2 class="st-heading-2"><strong>Analysts Favor Novavax Over Moderna</strong></h2><p>Koyfin data shows analysts assigning greater upside to Novavax than Moderna based on consensus price targets.</p><p>Moderna shares were last trading around $49.81 on Wednesday, but Wall Street’s expectations remain cautious. The stock’s average 12-month price target is $37.40, a 25% downside from current levels. Among the 24 analysts covering the company, the overall view sits at ‘Hold’, with two ‘Strong Buy’, two ‘Buy’, 17 ‘Hold’, one ‘Sell’, and two ‘Strong Sell’ ratings, giving Moderna an overall ‘Hold’ rating.</p><p>Meanwhile, Novavax last closed at $9.9 on Wednesday, and analysts see room for gains. The stock’s average 12-month price target of $12.89 points to a 30% upside&nbsp;from current levels. Among the nine analysts tracking the company, five rate it ‘Buy’, one ‘Hold’, one ‘Sell’, and two ‘Strong Sell’, giving Novavax an overall ‘Buy’ rating.</p><p>Over the past 12 months,&nbsp;<a href="https://stocktwits.com/symbol/NVAX">Novavax shares</a>&nbsp;have been up about 12%, while&nbsp;<a href="https://stocktwits.com/symbol/MRNA">Moderna</a> has gained roughly 39%.</p><h2 class="st-heading-2"><strong>Moderna Faces Analyst Caution</strong></h2><p>On Tuesday,&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/moderna-stock-still-worth-37-less-after-cancer-vaccine-data-bof-a-s-new-price-target-keeps-retail-traders-cautious/cmUDauIR4OV">Bank of America Securities raised its price target to $27 from $24</a> while keeping an ‘Underperform’ rating, implying a 37% downside based on the stock’s prior close near $43.</p><p>The update followed the release of&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/moderna-shares-rise-on-five-year-follow-up-takeaways-for-skin-cancer-vaccine/cmUuq4QR4OT">five-year follow-up data</a> for Moderna’s personalized cancer vaccine Intismeran Autogene, developed with Merck and used alongside Keytruda in patients with high-risk melanoma. Moderna and Merck said patients receiving the combination showed a 49% lower risk of cancer recurrence or death compared with Keytruda alone.&nbsp;</p><p>Earlier this month, UBS downgraded the stock to ‘Neutral’ from ‘Buy’ and cut its price target to $34 from $40, implying about 32% downside from its last close.&nbsp;</p><p>Moderna expects regulatory approvals this year for a standalone flu vaccine and a COVID-19/flu combination shot, though not in time for the 2026 respiratory season, with a potential boost in 2027. The company also expects key trial data in 2026, including late-stage norovirus results and mid-stage melanoma data.&nbsp;</p><h2 class="st-heading-2"><strong>Novavax In Focus</strong></h2><p>This week, Novavax&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-nvax-stock-rising-premarket-pfizer-matrix-m-deal/cmUumrjR4aq">signed a non-exclusive licensing deal with Pfizer</a> for up to two disease areas using its Matrix-M adjuvant. The deal includes a $30 million upfront payment, as well as the possibility of up to $500 million in development and sales milestones, and tiered royalties in the high mid-single-digit range.&nbsp;</p><p>That deal followed Novavax handing over U.S. and European rights to its Covid-19 vaccine candidate Nuvaxovid to Sanofi in November for undisclosed upfront payments and possible milestones. The deal also opens the door&nbsp;to future royalties. Novavax also has deals with Takeda and the Serum Institute of India.</p><p>Novavax has pushed its profitability target to 2028 as Covid-19 vaccine demand remains under pressure, while activist investor Shah Capital, which holds about 8.3%, has&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novavax-stock-faces-retail-backlash-as-shah-capital-warns-of-proxy-fight-and-presses-for-a-sale/cLPBFk7REdt">urged the board to review strategic alternatives</a>, including a potential sale.</p><h2 class="st-heading-2"><strong>Regulatory Backdrop</strong></h2><p>Uncertainty over regulatory approval also looms for both companies. Shares of Moderna and Novavax fell in December after an FDA memo to staff, which did not name a manufacturer, warned of safety problems with vaccines that could lead to tougher approval standards.</p><p>Novavax’s COVID-19 vaccine has full FDA approval with age- and risk-level-based restrictions, while Moderna's COVID-19 vaccines have full licensure across broader age groups.</p><h2 class="st-heading-2"><strong>How Did Stocktwits Users React?</strong></h2><p>On Stocktwits, retail sentiment toward Moderna was ‘extremely bullish’ amid ‘extremely high’ message volume, with watchers up 3% and message activity more than doubling over the past 12 months.</p><figure class="image"><img src="https://news.stocktwits-cdn.com/mrna_ss_png_124327497e.webp" alt="mrna ss.png" width="971" height="142"><figcaption>MRNA sentiment and message volume as of January 21 | Source: Stocktwits</figcaption></figure><p>On the other hand, retail sentiment toward Novavax was ‘extremely bullish’ amid ‘extremely high’ message volume, with watchers up 5% and message activity surging more than 600% over the past 12 months.</p><figure class="image"><img src="https://news.stocktwits-cdn.com/nvax_ss_png_ec285c2653.webp" alt="nvax ss.png" width="969" height="138"><figcaption>NVAX sentiment and message volume as of January 21 | Source: Stocktwits</figcaption></figure><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

 In this photo illustration vials of vaccines for coronavirus (COVID-19). Vaccines from left to right, Moderna, Bimervax, Comirnaty and Pfizer BioNTech. (Photo Illustration by Marcos del Mazo/LightRocket via Getty Images)

MRNA Vs NVAX: Which Vaccine Stock Is Wall Street More Bullish On Right Now?

Regulatory uncertainty remains a common factor for both companies following an FDA memo that raised concerns about vaccine safety.

Equity

Intel, Moderna, TMC, Microsoft And Lucid: Why These 5 Stocks Are On Investors' Radars Today

INTC, MRNA, TMC, MSFT, LCID were among the stocks seen trending on Wednesday, Jan. 21, 2026.read more...

Why Moderna Stock Surged Today

Key PointsModerna's and Merck's partnership could help to advance cancer care...

Moderna Stock Skyrockets To 52-Week High: What's Behind The Surge?

Moderna Inc (NASDAQ:MRNA) shares are trading higher on Wednesday on continued momentum after the company's Tuesday update revealing the long term results from a cancer therapy study.read more...

Moderna (NASDAQ:MRNA) Sets New 1-Year High - What's Next?

Moderna (NASDAQ:MRNA) Sets New 52-Week High - Here's Why...

Promising Biotech Stocks To Consider - January 21st

Moderna, ImmunityBio, Danaher, Vertex Pharmaceuticals, argenex, BioNTech, and Legend Biotech are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks...

Can HCA Q4 Earnings Withstand Higher Costs & Lower Outpatient Cases?

HCA Healthcare heads into Q4 earnings with solid admission and revenue growth, but rising costs and declining outpatient surgery cases cloud the odds of a beat.

Sumitomo Mitsui Trust Group Inc. Reduces Position in Moderna, Inc. $MRNA

Sumitomo Mitsui Trust Group Inc. reduced its position in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 86.1% in the 3rd quarter, according to the company in its most recent 13F filing with...

<ul class="summary-bullets"><li>BofA lifted its price target to $27 from $24 while keeping an 'Underperform' rating on the shares.</li><li>The update followed the release of five-year follow-up results for the Intismeran vaccine used alongside Keytruda in melanoma patients.</li><li>Moderna and Merck said additional data from the study will be shared at an upcoming medical meeting.</li></ul><p>Moderna Inc. shares were in focus on Wednesday after Bank of America Securities (BofA) raised its price target on the stock following new long-term data from the company’s experimental skin cancer vaccine developed with Merck, while keeping a bearish rating in place.</p><p>Merck shares rose 0.6% in regular trading before slipping 0.6% after hours, while Moderna climbed 2.8% during the session and edged 0.2% lower in extended trading.</p><h2 class="st-heading-2"><strong>Price Target Raised, Rating Maintained</strong></h2><p>BofA raised its price target on Moderna to $27 from $24 and reiterated an ‘Underperform’ rating on the shares. However, based on Moderna’s last closing price of $43, the updated target&nbsp;still implies about a 37% downside.</p><p>The firm said the increase followed the release of five-year data for Intismeran Autogene, Moderna’s personalized cancer vaccine, used in combination with Merck’s Keytruda in patients with high-risk melanoma.</p><p>While noting some upside potential, the brokerage pointed to challenges seen in similar combination treatments in the past, logistical challenges, and a “higher bar for success.” BofA said the higher price target reflects increased sales expectations for the vaccine in patients who have undergone surgery for melanoma.</p><h2 class="st-heading-2"><strong>Five-Year Skin Cancer Results</strong></h2><p>Moderna and Merck said the&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/moderna-shares-rise-on-five-year-follow-up-takeaways-for-skin-cancer-vaccine/cmUuq4QR4OT">latest follow-up</a> showed the vaccine combination continued to help patients remain cancer-free for longer than Keytruda alone.</p><p>After five years, patients who received the combination saw a 49% lower risk of the cancer returning or leading to death than those treated with Keytruda by itself. The companies said the findings build on earlier updates shared at the two-year and three-year marks. Moderna and Merck also said they plan to share additional follow-up results at an upcoming medical meeting.</p><h2 class="st-heading-2"><strong>Oncology Pipeline Progress</strong></h2><p>“Now with five years of follow-up data, today's results highlight the potential of a prolonged benefit of the intismeran autogene and Keytruda combination in patients with resected high-risk melanoma,” said Kyle Holen, Moderna’s head of oncology development.</p><p>Holen said the company continues to invest in cancer research and is preparing for several upcoming milestones, including results from a late-stage melanoma study being run with Merck, as well as progress across eight ongoing studies in different cancer types. Meanwhile, Merck’s head of oncology, Marjorie Green, said the long-term results are encouraging for patients&nbsp;at high risk of the disease returning after surgery.</p><p>Moderna said it is continuing to expand its cancer treatment work alongside its vaccine business. The company and Merck are currently running or enrolling studies across several cancers, including lung, bladder, kidney, and melanoma, as part of their joint development program for the vaccine.</p><h2 class="st-heading-2"><strong>How Did Stocktwits Users React?</strong></h2><p>On Stocktwits, retail sentiment was ‘neutral’ for Moderna and ‘bearish’ for Merck, with both seeing ‘normal’ message volume.</p><figure class="image"><img src="https://news.stocktwits-cdn.com/mrna_ss_png_65694a07b3.webp" alt="mrna ss.png" width="969" height="140"><figcaption>MRNA sentiment and message volume as of January 20 | Source: Stocktwits</figcaption></figure><figure class="image"><img src="https://news.stocktwits-cdn.com/mrk_ss_png_42eb55ab2c.webp" alt="mrk ss.png" width="961" height="141"><figcaption>MRK sentiment and message volume as of January 20 | Source: Stocktwits</figcaption></figure><p><a href="https://stocktwits.com/symbol/MRNA">Moderna’s stock</a> has risen 26% over the past 12 months, while Merck’s stock has jumped 16% over the same period.&nbsp;On Wall Street, analysts are largely neutral on MRNA, according to Koyfin data: 17 out of 24 analysts covering the stock recommend a ‘hold’ rating, while four have a ‘buy’ or ‘strong buy’ conviction, and the rest have a ‘sell’ rating. Their consensus price target of $​​36.75 leaves MRNA trading at a more than 14% premium.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Moderna headquarters, exterior view, Cambridge, Massachusetts, USA. (Photo by: Plexi Images/GHI/UCG/Universal Images Group via Getty Images)

Moderna Stock Still Worth 37% Less After Cancer Vaccine Data? BofA’s New Price Target Keeps Retail Traders Cautious

BofA Securities said the target hike reflects higher sales expectations, despite logistics challenges.

Moderna Merck Cancer Vaccine Shows Durable Benefit At 5 Years In High-Risk Melanoma

Moderna and Merck shared five-year study data showing their combined cancer treatment cut the risk of melanoma coming back or causing death by nearly half compared with Keytruda alone.read more...

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

Stocktwits

Stocktwits Polls

Investors are highly optimistic following strong five-year follow-up data for its partnered skin cancer vaccine, showing significant improvements in recurrence-free survival.

A powerful surge has trapped short sellers, leading to a scramble for cover as the stock rockets higher, eliciting celebratory taunts from long positions.

Bulls are confidently predicting the stock will reach or surpass $100, with many foreseeing a return to $200 or even higher amidst new developments.

The stock is displaying significant technical strength, with expanding volume and breaking out of a long downtrend, signaling renewed buying interest.

MRNA
Moderna Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest MRNA News

MRNAModerna Inc